Belite Bio Inc (BLTE) - Long-Term Debt to Capital Coefficient

Belite Bio, Inc (BLTE) is accelerating the development of ophthalmological treatments through the implementation of AI and production automation. Despite its scientific potential in combating age-related vision loss, the company currently lacks stable profit generators while awaiting the completion of clinical trials. This price chart, where the indicator stands at 0.00, prices in the risks of delayed drug approvals due to geopolitical tensions and regulatory restrictions in global research.

To assess the issuer's solvency, the long-term debt-to-equity ratio is used, which determines the company's degree of dependence on external borrowed financing over a long-term horizon. In the case of Belite Bio, Inc (BLTE), a low debt load in the history of long-term debt-to-equity minimizes default risk, ensuring financial stability for the completion of critical trials for the drug Tinlarebant.